Selarsdi Injection, Solution
Product Images NDC 51759-708

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Selarsdi (NDC 51759-708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Image 1)

An instructional diagram of a Selarsdi injection pen showing its parts labeled: plunger head, plunger, needle guard activation clips, needle guard wings, body, viewing window, label, needle, and needle cover. The device is designed for subcutaneous injection delivery.*

FDA Label Image

Image (Image 10)

An instructional illustration showing a hand holding a syringe with a needle inserted at a 45-degree angle into the skin. An arrow points to the injection site, indicating the proper angle for subcutaneous injection technique.*

FDA Label Image

Image (Image 11)

An instructional illustration depicting the subcutaneous injection of Selarsdi (ustekinumab-aekn) using a prefilled syringe. The image shows a hand holding the syringe at the injection site on the skin, demonstrating proper injection technique.*

FDA Label Image

Image (Image 12)

An instructional illustration showing the correct technique for administering a subcutaneous injection with a prefilled syringe. The illustration depicts a hand holding the syringe with the needle positioned to inject into the skin of another hand, demonstrating proper needle insertion and injection angle.*

FDA Label Image

Image (Image 13)

An instructional illustration labeled Figure I showing a hand holding a folded piece of gauze or cotton with a finger pressed against it. The image appears to demonstrate a step in a procedure involving the finger, likely related to injection site care or application of pressure after an injection.*

FDA Label Image

Image (Image 14)

An instructional illustration labeled 'Figure J' showing a syringe-like device being inserted into the top of a red container with a fitted lid, accompanied by an arrow indicating the downward motion of the device into the container. A stirring rod or stick is positioned to the right of the container.*

FDA Label Image

A (Image 15)

An instructional illustration labeled Figure A displaying items used with Selarsdi injection. It shows an adhesive bandage, antiseptic wipes, cotton ball or gauze pads, a vial labeled Selarsdi, a syringe with an attached needle, and an FDA-cleared sharps disposal container.*

FDA Label Image

B (Image 16)

Illustration showing recommended subcutaneous injection sites for Selarsdi (ustekinumab-aekn). Highlighted areas in orange include the front and outer thigh, the abdomen (avoiding the navel), the outer upper arm, and the upper buttocks of a human figure.*

FDA Label Image

C (Image 17)

Illustration labeled Figure C showing the removal of a vial cap by lifting it upward. The image depicts a vial with liquid inside and an arrow indicating the cap being taken off.*

FDA Label Image

D (Image 18)

Illustration showing hands opening a vial by lifting the protective cap upward, with an arrow indicating the direction to remove the cap. This instructional figure is likely related to the preparation or administration of Selarsdi (ustekinumab-aekn) injection solution.*

FDA Label Image

E (Image 19)

An instructional illustration showing two hands holding a syringe and cap. The right hand holds a syringe, while the left hand pulls the cap straight off, indicated by a double-headed horizontal arrow. The image demonstrates how to remove the cap from the syringe before use.*

FDA Label Image

Image (Image 2)

An instructional illustration showing a hand holding a syringe at an angle, administering an injection subcutaneously into the skin. An arrow above the syringe indicates the direction of movement during the injection process.*

FDA Label Image

F (Image 20)

An instructional illustration depicting hands preparing an injection by drawing medication from a vial into a syringe. This figure demonstrates a step in the preparation of a subcutaneous injection such as Selarsdi (ustekinumab-aekn) injection solution.*

FDA Label Image

G (Image 21)

An instructional black-and-white illustration showing hands drawing medication from a vial into a syringe. The vial is held upside down by one hand while the other hand pulls the syringe plunger to withdraw the solution.*

FDA Label Image

H (Image 22)

An instructional illustration depicting a hand holding a vial upside down while drawing medication into a syringe, with another hand poised to press the syringe plunger. This likely demonstrates preparation for subcutaneous injection of Selarsdi (ustekinumab-aekn) injection solution by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

I (Image 23)

An instructional illustration showing how to administer a subcutaneous injection at a 45-degree angle. The image depicts a hand holding a syringe and injecting into the skin of another person's forearm, demonstrating the proper injection technique.*

FDA Label Image

J (Image 24)

An instructional illustration showing a hand holding a syringe vertically above a surface, with an arrow pointing downward towards the syringe plunger, indicating injection technique or needle orientation.*

FDA Label Image

1 (Image 25)

Packaging label for Selarsdi (ustekinumab-aekn) Injection, 45 mg/0.5 mL, a single-dose prefilled syringe for subcutaneous use. The label includes dosage information, manufacturer Teva Pharmaceuticals USA, Inc., and instructions to discard unused portion. The label features the Selarsdi logo and product strength clearly displayed on a white and green background.*

FDA Label Image

1 (Image 26)

Selarsdi (ustekinumab-aekn) 90 mg/mL injection label for subcutaneous use. The label specifies a single-dose prefilled syringe containing 90 mg/mL solution. It includes dosage warnings, storage instructions, and pharmacist information. The labeler is Teva Pharmaceuticals USA, Inc., and the packaging features barcodes and lot details.*

FDA Label Image

1 (Image 27)

Selarsdi 130 mg/26 mL (5 mg/mL) injection for intravenous infusion. The label indicates the generic name ustekinumab-aekn and specifies it must be diluted before use. It contains one single-dose vial and is manufactured by Teva Pharmaceuticals USA, Inc. Packaging shows detailed dosing and storage instructions, including refrigeration requirements.*

FDA Label Image

1 (Image 28)

Packaging label for Selarsdi (ustekinumab-aekn) Injection 45 mg/0.5 mL by Teva Pharmaceuticals USA, Inc. The label indicates it is for subcutaneous use and includes dosage strength, usage instructions, and storage information. The package contains one single-dose vial with a note to discard any unused portion. The label also shows a barcode and a placeholder for lot and expiration details.*

FDA Label Image

Image (Image 3)

An instructional diagram showing a hand administering a subcutaneous injection. A syringe is depicted penetrating the skin at an angle, demonstrating the proper technique for injecting a solution beneath the skin.*

FDA Label Image

1 (Image 4)

A line graph comparing patient response percentages over 24 weeks for placebo, ustekinumab 45 mg, and ustekinumab 90 mg. The x-axis represents weeks from 0 to 24, and the y-axis shows the percentage of patients from 0% to 60%. The graph legend identifies three groups: placebo (n=206), ustekinumab 45 mg (n=205), and ustekinumab 90 mg (n=204).*

FDA Label Image

Image (Image 5)

An instructional diagram labeled Figure A showing components of a subcutaneous injection syringe. Parts identified include the plunger head, plunger, needle guard activation clips, needle guard wings, body, viewing window, label, needle, and needle cover. The syringe is depicted with a protective needle cover removed and all parts clearly labeled.*

FDA Label Image

Image (Image 6)

Figure B illustration showing components for Selarsdi injection administration: adhesive bandage, antiseptic wipes, cotton ball or gauze pad, Selarsdi prefilled syringe, and an FDA-cleared sharps disposal container. The drawing visually identifies each item typically used in preparing and disposing of the subcutaneous injection solution.*

FDA Label Image

Image (Image 7)

Illustration labeled Figure C showing recommended injection sites for Selarsdi (ustekinumab-aekn) subcutaneous injection. Areas highlighted in yellow include the front thigh, upper arm, abdomen, and buttocks, indicating preferred locations for injection administration.*

FDA Label Image

Image (Image 8)

Illustration showing hands preparing a syringe injection device by removing a protective cap or cover from the needle or pen tip, indicated by an upward arrow. The image depicts a step in preparing a subcutaneous injection.*

FDA Label Image

Image (Image 9)

An illustration labeled Figure E showing a hand holding a syringe with a plunger, preparing for injection. The diagram highlights the syringe components and hand placement, indicating its use for subcutaneous injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.